Our immune system generates a strong antibody response against nucleoproteins, but the role of this has not been understood. Leo James’ group has revealed a new mechanism that could have important implications for SARS-CoV-2 vaccination and treatment.
Human GPCRs are the targets of approximately 34% of all FDA-approved drugs. GPCRs in fungi could also be useful drug targets, but no structures of fungal GPCRs had been solved. Chris Tate’s group has now determined the first structure of a fungal GPCR.
Mitochondrial ribosomes are different from those in the cytoplasm of human cells and little is known about their quality control. Venki Ramakrishnan’s group has discovered a novel pathway to rescue stalled mitoribosomes and determined structures of the rescue factors.
Rebecca Taylor’s group has identified a signalling molecule that connects detection of a stressful environment by the nervous system with molecular defence mechanisms in other tissues and leads to changes in feeding behaviour and reproduction.
GPCRs are the target of approximately 34% of approved drugs, reflecting their key role in cell function. Madan Babu’s group has uncovered how different receptor isoforms, existing in different combinations, could generate tissue-specific responses to the same signal or drug.
The importance of our brain is reflected in the measures evolved to protect it, including the skull and meninges. However, its immune defence has been less well understood. Menna Clatworthy’s group has now identified immune cells derived from the gut defending the meninges.